Net Profit Margins
Ascendis Pharma A/S’s revenue jumped 11115% since last year same period to $2.24Mn in the Q3 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated -30.15% fall in its revenue since last 3-months.
Ascendis Pharma A/S’s net profit jumped 26.07% since last year same period to $-25.11Mn in the Q3 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated 57.37% jump in its net profits since last 3-months.
Ascendis Pharma A/S’s net profit margin jumped 99.34% since last year same period to -1119.62% in the Q3 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated 38.97% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter
EPS Estimate Current Year
Ascendis Pharma A/S’s earning per share (EPS) estimates for the current quarter stand at -2.6 - a 3.35% jump from last quarter’s estimates.
Ascendis Pharma A/S’s earning per share (EPS) estimates for the current year stand at -2.6.
Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Ascendis Pharma A/S’s earning per share (EPS) fell -106.12% since last year same period to -3.03 in the Q3 2022. This indicates that the Ascendis Pharma A/S has generated -106.12% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S’s return on assets (ROA) stands at -0.27.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S’s return on equity (ROE) stands at -0.67.
|Earnings Date||Estimated EPS||Reported EPS||Surprise %|
Ascendis Pharma A/S
Tuborg Boulevard 12, Hellerup, Denmark, 2900
Jan Moeller Mikkelsen
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*